{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T23:20:21Z","timestamp":1787008821197,"version":"build-2736575974"},"reference-count":34,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2020,10,10]],"date-time":"2020-10-10T00:00:00Z","timestamp":1602288000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,5,17]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Lenvatinib is used for unresectable hepatocellular carcinoma (u-HCC) as first-line, as well as second- and third-line therapy in Japan. We evaluated the therapeutic efficacy of newly developed ramucirumab when given after lenvatinib for post-progression treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Of 385 patients with u-HCC and treated with lenvatinib at 16 different institutions in Japan between May 2018 and January 2020, 28 who received ramucirumab as the next treatment were enrolled and therapeutic responses were evaluated in a retrospective manner.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The median age of the 28 patients given ramucirumab was 70\u2009years and the median albumin-bilirubin score was \u22122.19. Of the 28 patients, 23 were male, 21 were classified as Child\u2013Pugh A and 7 as Child\u2013Pugh B, and 25 were Barcelona Clinic Liver Cancer Stage C. Ramucirumab was given as second-line therapy in 14, third-line in 9, and fourth-line in 5. Therapeutic response was obtained in only 26 patients; the objective response rate was 3.8% (1\/26) and the disease-control rate was 42.3% (11\/26), with a median period to progression of 2.0\u2009months. The reasons for discontinuation of ramucirumab were progression of disease in 16 and Grade 3 adverse events (gastrointestinal bleeding, ascites) in 2.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The anticipated therapeutic efficacy of ramucirumab for post-progression treatment following lenvatinib was not seen in our early experience.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/gastro\/goaa042","type":"journal-article","created":{"date-parts":[[2020,6,12]],"date-time":"2020-06-12T07:37:30Z","timestamp":1591947450000},"page":"133-138","source":"Crossref","is-referenced-by-count":22,"title":["Therapeutic efficacy of ramucirumab after lenvatinib for post-progression treatment of unresectable hepatocellular carcinoma"],"prefix":"10.1093","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1989-0480","authenticated-orcid":false,"given":"Atsushi","family":"Hiraoka","sequence":"first","affiliation":[{"name":"Gastroenterology Center, Ehime Prefectural Central Hospital, Ehime, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Kumada","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Ogaki Municipal Hospital, Gifu, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshifumi","family":"Tada","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Himeji Red Cross Hospital, Hyogo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chikara","family":"Ogawa","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Takamatsu Red Cross Hospital, Takamatsu, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joji","family":"Tani","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Kagawa university, Kagawa, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinya","family":"Fukunishi","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Osaka Medical College, Osaka, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masanori","family":"Atsukawa","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology, Department of Internal Medicine, Nippon Medical School, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masashi","family":"Hirooka","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Metabology, Ehime University Graduate School of Medicine, Ehime, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kunihiko","family":"Tsuji","sequence":"additional","affiliation":[{"name":"Center of Gastroenterology, Teine Keijinkai Hospital, Sapporo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toru","family":"Ishikawa","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Saiseikai Niigata Hospital, Niigata, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koichi","family":"Takaguchi","sequence":"additional","affiliation":[{"name":"Department of Hepatology, Kagawa Prefectural Central Hospital, Takamatsu, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuya","family":"Kariyama","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Okayama City Hospital, Okayama, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ei","family":"Itobayashi","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Asahi General Hospital, Asahi, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuto","family":"Tajiri","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Toyama University Hospital, Toyama, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noritomo","family":"Shimada","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology, Otakanomori Hospital, Kashiwa, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Shibata","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Tokushima Prefectural Central Hospital, Tokushima, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hironori","family":"Ochi","sequence":"additional","affiliation":[{"name":"Hepato-biliary Center, Matsuyama Red Cross Hospital, Matsuyama, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuhito","family":"Kawata","sequence":"additional","affiliation":[{"name":"Department of Hepatology, Hamamatsu University School of Medicine, Hamamatsu, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hidenori","family":"Toyoda","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Ogaki Municipal Hospital, Gifu, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideko","family":"Ohama","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Osaka Medical College, Osaka, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuhiro","family":"Nouso","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Okayama City Hospital, Okayama, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akemi","family":"Tsutsui","sequence":"additional","affiliation":[{"name":"Department of Hepatology, Kagawa Prefectural Central Hospital, Takamatsu, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takuya","family":"Nagano","sequence":"additional","affiliation":[{"name":"Department of Hepatology, Kagawa Prefectural Central Hospital, Takamatsu, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norio","family":"Itokawa","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology, Department of Internal Medicine, Nippon Medical School, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Korenobu","family":"Hayama","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology, Department of Internal Medicine, Nippon Medical School, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taeang","family":"Arai","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology, Department of Internal Medicine, Nippon Medical School, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michitaka","family":"Imai","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Saiseikai Niigata Hospital, Niigata, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yohei","family":"Koizumi","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Metabology, Ehime University Graduate School of Medicine, Ehime, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinichiro","family":"Nakamura","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Himeji Red Cross Hospital, Hyogo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kojiro","family":"Michitaka","sequence":"additional","affiliation":[{"name":"Gastroenterology Center, Ehime Prefectural Central Hospital, Ehime, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoichi","family":"Hiasa","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Metabology, Ehime University Graduate School of Medicine, Ehime, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masatoshi","family":"Kudo","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Kindai University, Osaka, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"the Real-life Practice Experts for HCC (RELPEC) Study Group and HCC 48 Group (hepatocellular-carcinoma experts from 48 clinics in Japan)","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2020,10,10]]},"reference":[{"key":"2021051715091992200_goaa042-B1","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1056\/NEJMoa0708857","article-title":"Sorafenib in advanced hepatocellular carcinoma","volume":"359","author":"Llovet","year":"2008","journal-title":"N Engl J Med"},{"key":"2021051715091992200_goaa042-B2","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S1470-2045(08)70285-7","article-title":"Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial","volume":"10","author":"Cheng","year":"2009","journal-title":"Lancet Oncol"},{"key":"2021051715091992200_goaa042-B3","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/S0140-6736(16)32453-9","article-title":"Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"389","author":"Bruix","year":"2017","journal-title":"Lancet"},{"key":"2021051715091992200_goaa042-B4","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1016\/S0140-6736(18)30207-1","article-title":"Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial","volume":"391","author":"Kudo","year":"2018","journal-title":"Lancet"},{"key":"2021051715091992200_goaa042-B5","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1111\/hepr.13243","article-title":"Therapeutic potential of lenvatinib for unresectable hepatocellular carcinoma in clinical practice: multicenter analysis","volume":"49","author":"Hiraoka","year":"2018","journal-title":"Hepatol Res"},{"key":"2021051715091992200_goaa042-B6","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1002\/cam4.1909","article-title":"Clinical features of lenvatinib for unresectable hepatocellular carcinoma in real-world conditions: multicenter analysis","volume":"8","author":"Hiraoka","year":"2019","journal-title":"Cancer Med"},{"key":"2021051715091992200_goaa042-B7","doi-asserted-by":"crossref","first-page":"e0231427","DOI":"10.1371\/journal.pone.0231427","article-title":"Therapeutic efficacy of lenvatinib for patients with unresectable hepatocellular carcinoma based on the middle-term outcome","volume":"15","author":"Fuchigami","year":"2020","journal-title":"PLoS One"},{"key":"2021051715091992200_goaa042-B8","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1002\/jgh3.12209","article-title":"Early response and safety of lenvatinib for patients with advanced hepatocellular carcinoma in a real-world setting","volume":"4","author":"Sho","year":"2020","journal-title":"JGH Open"},{"key":"2021051715091992200_goaa042-B9","doi-asserted-by":"crossref","first-page":"754","DOI":"10.3390\/cancers12030754","article-title":"Early tumor shrinkage as a predictive factor for outcomes in hepatocellular carcinoma patients treated with lenvatinib: a multicenter analysis","volume":"12","author":"Takahashi","year":"2020","journal-title":"Cancers"},{"key":"2021051715091992200_goaa042-B10","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1001\/jamaoncol.2016.4115","article-title":"Ramucirumab as second-line treatment in patients with advanced hepatocellular carcinoma: analysis of REACH trial results by Child-Pugh score","volume":"3","author":"Zhu","year":"2017","journal-title":"JAMA Oncol"},{"key":"2021051715091992200_goaa042-B11","doi-asserted-by":"crossref","first-page":"e191","DOI":"10.1016\/S1470-2045(19)30165-2","article-title":"Ramucirumab in advanced hepatocellular carcinoma in REACH-2: the true value of alpha-fetoprotein","volume":"20","author":"Zhu","year":"2019","journal-title":"Lancet Oncol"},{"key":"2021051715091992200_goaa042-B12","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1002\/bjs.1800600817","article-title":"Transection of the oesophagus for bleeding oesophageal varices","volume":"60","author":"Pugh","year":"1973","journal-title":"Br J Surg"},{"key":"2021051715091992200_goaa042-B13","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1200\/JCO.2014.57.9151","article-title":"Assessment of liver function in patients with hepatocellular carcinoma: a new evidence-based approach: the ALBI grade","volume":"33","author":"Johnson","year":"2015","journal-title":"J Clin Oncol"},{"key":"2021051715091992200_goaa042-B14","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1111\/jgh.13250","article-title":"Usefulness of albumin-bilirubin grade for evaluation of prognosis of 2584 Japanese patients with hepatocellular carcinoma","volume":"31","author":"Hiraoka","year":"2016","journal-title":"J Gastroenterol Hepatol"},{"key":"2021051715091992200_goaa042-B15","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1159\/000452846","article-title":"Albumin-bilirubin (ALBI) grade as part of the evidence-based clinical practice guideline for HCC of the Japan Society of Hepatology: a comparison with the liver damage and Child-Pugh classifications","volume":"6","author":"Hiraoka","year":"2017","journal-title":"Liver Cancer"},{"key":"2021051715091992200_goaa042-B16","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1159\/000479984","article-title":"Validation and potential of albumin-bilirubin grade and prognostication in a nationwide survey of 46,681 hepatocellular carcinoma patients in Japan: the need for a more detailed evaluation of hepatic function","volume":"6","author":"Hiraoka","year":"2017","journal-title":"Liver Cancer"},{"key":"2021051715091992200_goaa042-B17","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1159\/000488778","article-title":"Validation of modified ALBI grade for more detailed assessment of hepatic function in hepatocellular carcinoma patients: a multicenter analysis","volume":"8","author":"Hiraoka","year":"2019","journal-title":"Liver Cancer"},{"key":"2021051715091992200_goaa042-B18","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"2021051715091992200_goaa042-B19","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1002\/hep.20933","article-title":"Management of hepatocellular carcinoma","volume":"42","author":"Bruix","year":"2005","journal-title":"Hepatology"},{"key":"2021051715091992200_goaa042-B20","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1148\/radiol.10091334","article-title":"Intraindividual comparison of gadoxetate disodium-enhanced MR imaging and 64-section multidetector CT in the Detection of hepatocellular carcinoma in patients with cirrhosis","volume":"256","author":"Di Martino","year":"2010","journal-title":"Radiology"},{"key":"2021051715091992200_goaa042-B21","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1148\/radiol.11101840","article-title":"Imaging study of early hepatocellular carcinoma: usefulness of gadoxetic acid-enhanced MR imaging","volume":"261","author":"Sano","year":"2011","journal-title":"Radiology"},{"key":"2021051715091992200_goaa042-B22","doi-asserted-by":"crossref","first-page":"57","DOI":"10.3892\/ol_00000010","article-title":"Clinical translation in the treatment of hepatocellular carcinoma following the introduction of contrast-enhanced ultrasonography with Sonazoid","volume":"1","author":"Hiraoka","year":"2010","journal-title":"Oncol Lett"},{"key":"2021051715091992200_goaa042-B23","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1111\/j.1440-1746.2011.06678.x","article-title":"New contrast enhanced ultrasonography agent: impact of Sonazoid on radiofrequency ablation","volume":"26","author":"Hiraoka","year":"2011","journal-title":"J Gastroenterol Hepatol"},{"key":"2021051715091992200_goaa042-B24","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1016\/S0140-6736(18)30010-2","article-title":"Hepatocellular carcinoma","volume":"391","author":"Forner","year":"2018","journal-title":"Lancet"},{"key":"2021051715091992200_goaa042-B25","first-page":"26","volume-title":"The General Rules For The Clinical And Pathological Study of Primary Liver Cancer","year":"2015","edition":"6th edn"},{"key":"2021051715091992200_goaa042-B26"},{"key":"2021051715091992200_goaa042-B27","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1038\/bmt.2012.244","article-title":"Investigation of the freely available easy-to-use software \u2018EZR\u2019 for medical statistics","volume":"48","author":"Kanda","year":"2013","journal-title":"Bone Marrow Transplant"},{"key":"2021051715091992200_goaa042-B28","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.21873\/anticanres.14167","article-title":"Initial experience of ramucirumab treatment after lenvatinib failure for patients with advanced hepatocellular carcinoma","volume":"40","author":"Kuzuya","year":"2020","journal-title":"Anticancer Res"},{"key":"2021051715091992200_goaa042-B29","doi-asserted-by":"crossref","first-page":"536","DOI":"10.3390\/cells8060536","article-title":"FGF19-FGFR4 signaling in hepatocellular carcinoma","volume":"8","author":"Raja","year":"2019","journal-title":"Cells"},{"key":"2021051715091992200_goaa042-B30","doi-asserted-by":"crossref","first-page":"viii17","DOI":"10.1093\/annonc\/mdy269.057","article-title":"Final analysis of serum biomarkers in patients (pts) from the phase III study of lenvatinib (LEN) vs sorafenib (SOR) in unresectable hepatocellular carcinoma (uHCC) [REFLECT]","volume":"29","author":"Finn","year":"2018","journal-title":"Ann Oncol"},{"key":"2021051715091992200_goaa042-B31","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1038\/sj.onc.1210623","article-title":"Targeting FGF19 inhibits tumor growth in colon cancer xenograft and FGF19 transgenic hepatocellular carcinoma models","volume":"27","author":"Desnoyers","year":"2008","journal-title":"Oncogene"},{"key":"2021051715091992200_goaa042-B32","doi-asserted-by":"crossref","first-page":"e36713","DOI":"10.1371\/journal.pone.0036713","article-title":"Targeting FGFR4 inhibits hepatocellular carcinoma in preclinical mouse models","volume":"7","author":"French","year":"2012","journal-title":"PLoS One"},{"key":"2021051715091992200_goaa042-B33","doi-asserted-by":"crossref","first-page":"1916","DOI":"10.1007\/s10620-013-2609-x","article-title":"Expression of fibroblast growth factor 19 is associated with recurrence and poor prognosis of hepatocellular carcinoma","volume":"58","author":"Hyeon","year":"2013","journal-title":"Dig Dis Sci"},{"key":"2021051715091992200_goaa042-B34","doi-asserted-by":"crossref","first-page":"294","DOI":"10.3390\/diseases3040294","article-title":"Targeting FGF19\/FGFR4 pathway: a novel therapeutic strategy for hepatocellular carcinoma","volume":"3","author":"Repana","year":"2015","journal-title":"Diseases"}],"container-title":["Gastroenterology Report"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/gastro\/article-pdf\/9\/2\/133\/37944300\/goaa042.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/gastro\/article-pdf\/9\/2\/133\/37944300\/goaa042.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,17]],"date-time":"2021-05-17T11:13:14Z","timestamp":1621249994000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/gastro\/article\/9\/2\/133\/5920587"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,10]]},"references-count":34,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2020,10,10]]},"published-print":{"date-parts":[[2021,5,17]]}},"URL":"https:\/\/doi.org\/10.1093\/gastro\/goaa042","relation":{},"ISSN":["2052-0034"],"issn-type":[{"value":"2052-0034","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,4,1]]},"published":{"date-parts":[[2020,10,10]]}}}